Oncopeptides AB (publ) (ONCO) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to Oncopeptide's second quarter earnings call for 2026. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing pound key 5 on their telephone keypad. Now I will hand the conference over to CEO Sophia Haggis and CFO Henrik Bergentoft. Please go ahead. Welcome to the Oncopeptides webcast for the second quarter of 2026. Please note the disclaimer regarding forward-looking statements. Today's presentation is led by me, Sofia Heggis, and our CFO, Henrik Bergentoft. We delivered net sales of 31.1 million SEK in Q2 2026, representing a 62% increase compared to Q2 2025. For the first half of the year, net sales reached 56.5 million SEK, up with 74% year over year. Following the rights issue completed earlier this year, our cash position stood at 158 million SEK at the end of the second quarter. we remain on track towards reaching positive cash flow during 2027. During the second quarter, we achieved several critical commercial, clinical and regulatory milestones, which demonstrates that even though our organization is lean, oncopeptides consists of people with high level of competence, motivation level and drive. We submitted our type 2 variation application to the EMA to expand PEPAXTI's label into third-line multiple myeloma patients. Preclinical data for our novel NK cell engager was presented at the AACR annual meeting. We presented five scientific abstracts and hosted a well-attended PDC symposium at the EHA Congress right here in Stockholm. In Germany, the first patient was enrolled in our non-interventional real-world evidence study Marina. Outside of multiple myeloma, we received regulatory approval from Norwegian authorities and enrol...